Rare PIK3CA hotspot mutations in carcinomas of the biliary tract - PubMed (original) (raw)
Rare PIK3CA hotspot mutations in carcinomas of the biliary tract
Marc-Oliver Riener et al. Genes Chromosomes Cancer. 2008 May.
Abstract
Somatic mutations of the PIK3CA gene, which encodes the p110alpha catalytic subunit of phosphatidylinositol 3-kinase (PI3K), are frequent in various cancer types. The majority of mutations cluster at hotspots within exons 9 and 20, which encode the helical and kinase domains of p110alpha. PIK3CA mutations in bile duct and gallbladder carcinomas have not been reported yet. In this study, we analysed 118 carcinomas of the biliary tract and the liver (45 intra- and extrahepatic cholangiocarcinomas (CCA), 23 gallbladder carcinomas, 50 hepatocellular carcinomas) for PIK3CA hotspot mutations using polymerase chain reaction and direct DNA sequencing. PIK3CA missense mutations were found in one of 11 intrahepatic CCA (E545K, 9%), one of 23 gallbladder carcinomas (E542K, 4%), and one of 50 hepatocellular carcinomas (H1047R, 2%). All three mutations represent hotspot mutations, which also occur in other cancer types. PI3K pathway activation in hepato-biliary carcinomas was analyzed using immunohistochemistry for the downstream targets eIF4-E and phosphorylated 4E-BP1 on tissue microarrays. eIF4-E expression was found in 3/13 intrahepatic CCA (23%), 9/38 extrahepatic CCA (24%), 12/34 gallbladder carcinomas (35%), and 9/61 hepatocellular carcinomas (15%). 4E-BP1 phosphorylation was observed in 1/13 intrahepatic CCA (8%), 8/38 extrahepatic CCA (21%), 15/34 gallbladder carcinomas (44%), and 16/61 hepatocellular carcinomas (26%). These results indicate that somatic PIK3CA mutations contribute to the frequent activation of the PI3K/AKT pathway in carcinomas of the biliary tract and liver.
(c) 2008 Wiley-Liss, Inc.
Similar articles
- Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients.
Tanaka Y, Kanai F, Tada M, Asaoka Y, Guleng B, Jazag A, Ohta M, Ikenoue T, Tateishi K, Obi S, Kawabe T, Yokosuka O, Omata M. Tanaka Y, et al. Oncogene. 2006 May 11;25(20):2950-2. doi: 10.1038/sj.onc.1209311. Oncogene. 2006. PMID: 16331247 - Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas.
Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M, Ferro A, Dalla Palma P, Galligioni E, Marchetti A. Barbareschi M, et al. Clin Cancer Res. 2007 Oct 15;13(20):6064-9. doi: 10.1158/1078-0432.CCR-07-0266. Clin Cancer Res. 2007. PMID: 17947469 - Frequent mutation of the PIK3CA gene in ovarian and breast cancers.
Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI, Boyd J. Levine DA, et al. Clin Cancer Res. 2005 Apr 15;11(8):2875-8. doi: 10.1158/1078-0432.CCR-04-2142. Clin Cancer Res. 2005. PMID: 15837735 - Oncogenic PI3K deregulates transcription and translation.
Bader AG, Kang S, Zhao L, Vogt PK. Bader AG, et al. Nat Rev Cancer. 2005 Dec;5(12):921-9. doi: 10.1038/nrc1753. Nat Rev Cancer. 2005. PMID: 16341083 Review. - Cancer-specific mutations in phosphatidylinositol 3-kinase.
Vogt PK, Kang S, Elsliger MA, Gymnopoulos M. Vogt PK, et al. Trends Biochem Sci. 2007 Jul;32(7):342-9. doi: 10.1016/j.tibs.2007.05.005. Epub 2007 Jun 11. Trends Biochem Sci. 2007. PMID: 17561399 Review.
Cited by
- Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes.
Machado-Neto JA, Traina F, Lazarini M, Campos Pde M, Pagnano KB, Lorand-Metze I, Costa FF, Saad ST. Machado-Neto JA, et al. Clinics (Sao Paulo). 2011;66(5):793-9. doi: 10.1590/s1807-59322011000500014. Clinics (Sao Paulo). 2011. PMID: 21789382 Free PMC article. - Signaling pathways as therapeutic targets in biliary tract cancer.
Yang J, Farren MR, Ahn D, Bekaii-Saab T, Lesinski GB. Yang J, et al. Expert Opin Ther Targets. 2017 May;21(5):485-498. doi: 10.1080/14728222.2017.1306055. Epub 2017 Mar 17. Expert Opin Ther Targets. 2017. PMID: 28282502 Free PMC article. Review. - Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy.
Carotenuto M, Sacco A, Forgione L, Normanno N. Carotenuto M, et al. Explor Target Antitumor Ther. 2022;3(2):200-223. doi: 10.37349/etat.2022.00079. Epub 2022 Apr 26. Explor Target Antitumor Ther. 2022. PMID: 36046845 Free PMC article. Review. - Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma.
Du J, Lv X, Zhang Z, Huang Z, Zhang E. Du J, et al. Front Immunol. 2023 Mar 1;14:1142690. doi: 10.3389/fimmu.2023.1142690. eCollection 2023. Front Immunol. 2023. PMID: 36936931 Free PMC article. Review. - A perspective on molecular therapy in cholangiocarcinoma: present status and future directions.
Andersen JB, Thorgeirsson SS. Andersen JB, et al. Hepat Oncol. 2014 Jan 1;1(1):143-157. doi: 10.2217/hep.13.4. Hepat Oncol. 2014. PMID: 24772266 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous